Castle Biosciences Inc. has recently updated its shareholder information through a filing by Principal Global Investors. The filing indicates that Principal Global now holds approximately 1,500,897 shares, which represents about 4.9% of Castle Biosciences' common stock. This development is significant as it highlights the increasing interest in the medical laboratory services sector.

Background

Castle Biosciences Inc. operates in the medical laboratories sector, specifically under the SIC code 8071. The company is publicly traded on the Nasdaq under the ticker symbol CSTL. Based in Friendswood, Texas, Castle Biosciences focuses on providing innovative diagnostic solutions to improve patient outcomes.

What the Filing Says

The recent filing, submitted on October 29, 2026, indicates that Principal Global Investors has beneficially owned 1,500,897 shares of Castle Biosciences. The filing states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business." This suggests that the shares were not acquired for the purpose of influencing control over Castle Biosciences.

Impact

This increase in stake by Principal Global Investors could affect the dynamics of shareholder influence within Castle Biosciences. As a significant institutional investor, Principal Global's actions may carry weight in future corporate decisions. The filing indicates that the shares are held in the ordinary course of business, which means they are not intended for immediate sale or to exert control over the company.

What's Next

The filing does not say what happens next.